諾華的山德士計劃到2020年前上市5個生物類似物垂寥，包括修美樂粗截、類克巍棱、美羅華含滴、恩利和長效G－CSF氢拥。有意思的是山德士的頭Richard Francis說：公司可以成為付費(fèi)方和健康系統(tǒng)的真正伙伴虽另，以確保他們能管理他們的預(yù)算暂刘。顯然這句話在中國不適用，因?yàn)槲覀兊母顿M(fèi)方和健康系統(tǒng)有強(qiáng)大的招(keng)標(biāo)(die)機(jī)制和早已上市的仿制品捂刺。
原文如下：
Novartis unveils plans to launch several biosimilars by 2020
(Ref: Sandoz, Business Finance News, Business Insider)
June 20th, 2016
By: Joe Barber
Novartis on Monday announced that progress in its biologics pipeline "paves the way" for five planned global launches of biosimilar products by 2020. Richard Francis, head of Novartis' Sandoz unit, suggested "we are committed to significantly broadening patient access to biologics…over the next few years," adding that the company "can become a real partner for payers and healthcare systems in making sure they can manage their budgets."
Francis specified that Novartis will likely launch biosimilar versions of AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept) and Neulasta (pegfilgrastim), Johnson & Johnson's Remicade (infliximab) and Roche's Rituxan (rituximab) within the next four years. The five drugs amassed combined sales of approximately $44 billion in 2015, according to Novartis.
The company indicated that it would pursue an "aggressive" strategy that involves the submission of 11 regulatory filings between 2015 and 2017, noting that Sandoz has already announced six of these in the last 12 months. Most recently, the European Medicines Agency accepted the drugmaker's submission for its Rituxan biosimilar in May. Meanwhile, Novartis said Sandoz's early-stage pipeline includes assets in oncology and other specialty therapeutic areas, "with plans to start new programmes every year." The company also suggested that investments of more than $1 billion, from 2010 through to 2020, in two bio-manufacturing facilities in Austria "position Sandoz to deliver biosimilars at an unprecedented scale."
Novartis launched its Omnitrope (somatropin) biosimilar referencing Pfizer's recombinant human growth hormone Genotropin (somatropin) in Europe in 2006, marking the first availability of a biosimilar therapy anywhere globally. Novartis later became the first company to receive Japanese approval of a biosimilar when regulators there cleared Somatropin in 2009, while Zarxio (filgrastim-sndz), its follow-on version of Amgen's Neupogen (filgrastim), was launched in the US last year.
